Beckley Psytech Reports Positive Results for Alcohol Use Disorder Treatment
Beckley Psytech has announced encouraging results from a Phase IIa clinical trial of BPL-003, a synthetic 5-MeO-DMT formulation, for alcohol use disorder. The UK-based company, focused on psychedelic medicine, shared data suggesting BPL-003 could offer significant therapeutic benefits to patients struggling with this condition.
New: Interested in Being Part of a Psychedelics-Focused Clinical Trial? Sign Up Here
Study Design and Key Findings
The trial evaluated BPL-003 in combination with psychotherapy among patients diagnosed with moderate to severe alcohol use disorder. The study measured reductions in alcohol consumption and improvements in psychological well-being. Results showed the treatment was well tolerated and led to a meaningful reduction in heavy drinking days for participants. These findings align with growing evidence suggesting psychedelic-assisted therapies may address addiction in ways traditional treatments have struggled to achieve.
Most clinics spend 4-6 weeks navigating Spravato REMS certification — chasing paperwork, decoding FDA requirements, and wondering if they missed a step. Our AI-powered REMS Certification Assistant cuts that to one sitting. Get a personalized checklist of exactly what you need, and walk into the REMS portal ready to submit.
Get the REMS Certification Assistant →Looking for treatment? Find ketamine clinics closest to you as well as other psychedelic therapies in your area.
Here’s a breakdown of the timeline of Beckley Psytech’s study on BPL-003 for alcohol use disorder:
| Stage | Timeline | Key Milestones |
|---|---|---|
| Preclinical Development | Prior to clinical trials | Development of BPL-003 and preclinical safety testing completed. |
| Phase I | Completed before Phase IIa | Assessed the safety, tolerability, and pharmacological profile of BPL-003. |
| Phase IIa Study Launch | Early 2023 (estimated) | Initiated study to evaluate BPL-003 in patients with moderate to severe alcohol use disorder. |
| Study Completion | Late 2024/Early 2025 (estimated) | Conducted trial with results showing meaningful reductions in heavy drinking days. |
| Data Announcement | January 2025 | Announced positive topline data from the Phase IIa study, highlighting safety and efficacy. |
| Next Steps | 2025 and beyond | Plan to initiate larger-scale Phase IIb or III trials to further assess treatment outcomes. |
Expanding Treatment Options
Alcohol use disorder affects millions globally, with many patients experiencing limited success using conventional interventions. Beckley Psytech’s data underscores the potential of BPL-003 as a transformative approach for patients who have not responded to existing treatments. This development could mark a step forward in combating one of the world’s most pervasive public health challenges.
Next Steps for BPL-003
The company plans to advance its research by initiating further clinical trials. These will assess the efficacy and safety of BPL-003 on a larger scale, paving the way for possible regulatory approval. Beckley Psytech’s work highlights the broader trend of using psychedelics to treat complex mental health conditions, a field that has gained momentum in recent years.
This study demonstrates the growing potential of psychedelic-assisted therapies to address pressing medical needs. As research continues, BPL-003 could represent a new frontier in addiction treatment.
